menu search

SRPT / 7 Biotech Stocks That Will Make You Rich in 10 Years

7 Biotech Stocks That Will Make You Rich in 10 Years
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster. Read More
Posted: Jan 18 2023, 15:44
Author Name: InvestorPlace
Views: 103011

SRPT News  

Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test

By Investors Business Daily
October 31, 2023

Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results. more_horizontal

Sarepta Stock Sinks on Mixed Gene Therapy Results

By Barrons
October 31, 2023

Sarepta Stock Sinks on Mixed Gene Therapy Results

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met. more_horizontal

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy

By Investors Business Daily
October 30, 2023

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted. more_horizontal

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

By Reuters
October 30, 2023

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company re more_horizontal

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

By The Motley Fool
August 23, 2023

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some impo more_horizontal

Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 2, 2023

Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Directo more_horizontal

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 2, 2023

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to more_horizontal

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

By Zacks Investment Research
July 25, 2023

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared more_horizontal


Search within

Pages Search Results: